Learn more on this topic: Advances in Extended Adjuvant HER2-Positive Early Breast Cancer

How do I select patients for treatment with extended adjuvant therapies such as neratinib?

G. Thomas Budd, MD

G. Thomas Budd, MD, on advances in extended adjuvant HER2+ early breast cancer.

Copyright © 2010-2020 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.